ENESTfreedom Study Reports Durable Treatment-Free Remission in Chronic Myeloid Leukemia After 96 Weeks
Nearly half of patients with CML who achieved a deep molecular response following treatment with nilotinib remained in remission for 96 weeks.
All articles by Alexander M. Castellino, PhD
Long-Term Follow Up of CheckMate 205 Confirms Nivolumab Efficacy in Relapsed/Refractory Hodgkin Lymphoma
Similar ORR was reported for patients regardless of prior exposure to brentuximab vedotin (BV).
Nimotuzumab in Combination With Concurrent Radiotherapy and Cisplatin Is Active in Locally Advanced SCCHN
Nimotuzumab in combination with concurrent radiotherapy and cisplatin provides significant clinical benefits in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Women With Head and Neck Cancer Receive Less Treatment and Have Inferior Outcomes Compared With Men
When variables such as age and serious medical conditions were accounted for cancer versus non-cancer mortality was two times higher for women compared with men.
SANDPIPER: First Trial to Show Modest Benefit of Taselisib in Postmenopausal Women With ER+/HER- Advanced Breast Cancer
Despite modest improvements in progression-free survival, patients experienced considerable side effects with the addition of taselisib.
PALOMA 3: Elucidating Resistance Mechanisms to Palbociclib and Fulvestrant
It is important to understand mechanisms of resistance with these inhibitors to determine future treatment strategies.
MONALEESA 3: Ribociclib Provides Significant PFS in Postmenopausal Women With ER+/HER- Advanced Breast Cancer Regardless of Prior Endocrine Therapy
With a greater than 40% decreased risk for disease progression, the combination of ribociclib and fulvestrant was significantly better than that of placebo and fulvestrant for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer.
Future Treatment Modalities in Sarcoma: Insights From ASCO 2017
Targeted and immunotherapeutic approaches are poised to change how sarcoma will be treated in the future. Trials are being used to match tumors with appropriate treatment choices.
Overcoming Drug Resistance in the Treatment of Metastatic Breast Cancer
The management of metastatic breast cancer resistant or refractory to hormonal treatments, while still challenging, is rapidly improving.
Maintenance Pembrolizumab Does Not Improve PFS in Small-cell Lung Cancer
Maintenance pembrolizumab does not prolong progression-free survival, though it may improve overall survival, among patients with extensive-stage small-cell lung cancer.
- Loading...
Loading...
Next post in Lung Cancer
Loading... 
Loading...